Nivolumab-induced pneumonitis and cardiopathy in a patient with relapsed Hodgkin's lymphoma
{{output}}
Introduction: Nivolumab, the monoclonal antibody inhibitor of programmed cell death protein 1, enhances the T-cell response, including anti-tumour responses, by blocking the attachment of programmed death-ligand 1 and programmed ... ...
